Also trades as: PHASQ (OTC) · $vol 0M
PHAS NASDAQ
PhaseBio Pharmaceuticals, Inc.
1W: -42.4%
1M: -62.8%
3M: -94.3%
1Y: -98.3%
3Y: -98.4%
$0.07
Last traded 2022-11-02 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$11K
-96.6% ▼
Gross Profit
$11K
+3284.7% ▲
Operating Income
-$130K
+99.8% ▲
Net Income
-$131K
+99.9% ▲
EPS (Diluted)
$-0.00
+99.9% ▲
EBITDA
$2M
+101.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $668K | $2M | $320K | $11K |
| YoY Growth | +0.0% | +0.0% | +253.4% | -86.4% | -96.6% |
| Cost of Revenue | $0 | $0 | $0 | $320K | $0 |
| Gross Profit | $0 | $668K | $2M | $320 | $11K |
| Gross Margin | — | 100.0% | 100.0% | 0.1% | 100.0% |
| R&D Expenses | $6M | $15M | $31M | $72M | $102K |
| SG&A Expenses | $2M | $5M | $11M | $13M | $16K |
| Operating Expenses | $9M | $20M | $42M | $85M | $118K |
| Operating Income | -$9M | -$20M | -$40M | -$85M | -$130K |
| Operating Margin | — | -2940.7% | -1683.0% | -26517.5% | -1204.1% |
| Interest Expense | $3M | $4M | $1M | $1M | -$947 |
| Income Before Tax | -$10M | -$24M | -$39M | -$99M | -$129K |
| Tax Expense | $0 | $0 | $0 | $0 | $2K |
| Net Income | -$10M | -$24M | -$39M | -$99M | -$131K |
| Net Margin | — | -3569.8% | -1662.3% | -30801.6% | -1210.1% |
| EPS (Diluted) | $-0.91 | $-4.49 | $-1.43 | $-3.39 | $-0.00 |
| EBITDA | -$7M | -$20M | -$38M | -$97M | $2M |
| Shares Outstanding | 11M | 5M | 27M | 29M | 29M |